# Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer

> **NCT01354379** · PHASE1 · COMPLETED · sponsor: **NanoBio Corporation** · enrollment: 125 (actual)

## Conditions studied

- Healthy Adult Volunteers

## Interventions

- **BIOLOGICAL:** NB-1008
- **BIOLOGICAL:** Fluzone IN

## Key facts

- **NCT ID:** NCT01354379
- **Lead sponsor:** NanoBio Corporation
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-05
- **Primary completion:** 2012-06
- **Final completion:** 2012-07
- **Target enrollment:** 125 (ACTUAL)
- **Last updated:** 2013-03-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01354379

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01354379, "Safety and Immunogenicity Study of Inactivated Nasal Influenza Vaccine NB-1008 Administered by Sprayer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT01354379. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*